Fiche publication
Date publication
décembre 2020
Journal
Multiple sclerosis and related disorders
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Ayrignac X, Bigaut K, Pelletier J, de Seze J, Demortiere S, Collongues N, Maarouf A, Pinna F, Aouinti S, Carra Dallière C, Kremer L, Charif M, Picot MC, Labauge P
Lien Pubmed
Résumé
The advent of new, potent, disease-modifying therapies has dramatically changed the management of multiple sclerosis (MS). Along with these possibilities, it is crucial to better recognize patients who are at risk of first line treatment (FLT) failure and switch to highly effective therapies (HET).
Mots clés
Disease modifying therapies, Multiple sclerosis, Prognosis, Treatment failure, Treatment switch
Référence
Mult Scler Relat Disord. 2020 Dec 13;48:102686
